Cencora, Inc. (COR) · Aug 5, 2026 · Company update

Earnings and revenue beat; outlook rises only modestly on buybacks.

Earnings and revenue beat; outlook rises only modestly on buybacks.

The quarter cleared the standing bar on both sales and adjusted profit. Adjusted EPS of $4.48 exceeded the published consensus of roughly $4.36, while revenue of $84.8B was modestly above the roughly $84.35B expectation. The beat was supported by a 15-basis-point expansion in adjusted operating margin to 1.46%, not just higher volume. (Quarterly Results; Non-GAAP Reconciliation; Segment Results)

MetricQ3 FY2026 actualQ3 FY2025Published expectation / prior outlook
Revenue$84.8B, +5.1%$80.7B~$84.35B consensus (Quarterly Results)
Adjusted diluted EPS$4.48, +12.0%$4.00~$4.36 consensus (Non-GAAP Reconciliation)
Adjusted operating income$1.24B, +17.0%$1.06B— (Non-GAAP Reconciliation)
Adjusted operating margin1.46%, +15 bps1.31%— (Segment Results)
FY2026 adjusted EPS guidance$17.75–$17.95—$17.70–$17.90 previously (Fiscal Year 2026 Guidance)
Nine-month adjusted free cash flow$1.14B—~$3.0B full-year target unchanged (Cash Flow; Adjusted Free Cash Flow Reconciliation; Fiscal Year 2026 Guidance)

The outlook raise is real but narrow, which tempers an otherwise stronger quarter. The adjusted-EPS range moved up by only $0.05 at each end, to a midpoint of $17.85—above the previously published consensus near $17.76. But revenue growth, adjusted operating-income growth, free-cash-flow, capital-spending, and interest-expense targets were left unchanged. Management explicitly ties the update in part to completing $1.0B of repurchases earlier than planned, so this is more of an EPS/share-count upgrade than a broad upgrade to operating assumptions. (Fiscal Year 2026 Guidance; Quarterly Results)

Underlying profitability improved, though the acquisition is doing meaningful work. U.S. Healthcare Solutions revenue grew 4.9%, but segment operating income rose 15.9%; International operating income rose 20.8%. The margin lift reflects OneOncology and higher pharmaceutical sales, while GLP-1 sales remain a mix headwind because they carry lower gross margins. Since OneOncology closed in February, its contribution was already known; the positive surprise is that combined profit conversion still exceeded expectations. (Segment Results — U.S. Healthcare Solutions; Segment Results — International Healthcare Solutions)

The cleaner adjusted result matters more than the GAAP headline. GAAP EPS was $3.94, but it included a larger LIFO inventory credit and an $88.6M litigation/opioid-related credit; adjusted EPS removes those items along with acquisition and restructuring costs. The $4.48 adjusted figure therefore provides the better read on the quarter's operating beat. (GAAP to Non-GAAP Reconciliation)

The trade-off remains a more leveraged post-acquisition balance sheet. Net interest expense rose 72% year over year to $140.7M as debt funded OneOncology, and long-term debt stood at $11.44B at June 30 versus $7.54B at fiscal year-end. Operating cash flow improved sharply year over year, but cash fell to $2.82B after acquisition spending, buybacks, and financing activity. That does not undo the earnings beat, but it limits how much of the stronger profit can be treated as cost-free. (Quarterly Results; Balance Sheet; Cash Flow Statement)

Original filing on SEC EDGAR

More Cencora, Inc. news

Earnings and revenue beat; outlook rises only modestly on buybacks. | COR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.